{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '1. LFT results are to be obtained within 7 days prior to dosing and results are to be reviewed', 'prior to each dose of fitusiran. Central laboratory results are preferable. If not available,', 'local laboratory results may be used; however, if a local assessment is drawn, a serum', 'chemistry sample must also be drawn for analysis at the central laboratory.', '2. For any ALT or AST elevation >3x ULN central laboratory results should be used to', 'guide subsequent monitoring as detailed in Table 3.', '3. For any ALT or AST elevation >3x ULN:', 'a. Confirm using central laboratory, as soon as possible, ideally within 2 to 3 days, but', 'no later than 7 days.', 'b. Perform assessments per Table 3 and Table 6.', 'c. If an alternative cause is found, provide appropriate care.', '4. For any ALT or AST elevation >3x ULN without alternative cause that is accompanied', 'by clinical symptoms consistent with liver injury (eg nausea, right upper quadrant', 'abdominal pain, jaundice) or elevated bilirubin to >2x ULN or INR >1.5, permanently', 'discontinue dosing.', '5. For confirmed ALT or AST elevations >3x ULN without alternative cause and not', 'accompanied by symptoms or elevated bilirubin >2x ULN or INR 1.5, see Table 3', 'below:', 'Property of the Sanofi Group - strictly confidential', '43', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Table 3: Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed', 'Isolated Elevations of ALT and/or AST >3x ULN, with No Alternative Cause Identified', 'Transaminase Level', 'Action', '>3x to 5x ULN', 'May continue dosing', 'Evaluate the initial elevation in LFT per the following', 'assessments:', 'Table 6 (all assessments to be performed once)', 'Hematology, serum chemistry, LFT, and coagulation per', 'Table 5', 'AT', 'Monitor at least every two weeks (hematology, serum chemistry,', 'LFT, and coagulation per Table 5 and AT)', 'If elevation persists for >2 months, must discuss with the study', 'Medical Monitor before continuing dosing', '>5x to 8x ULN', 'Hold fitusiran dose until recovery to <1.5x ULN; may resume', 'dosing after discussion with the study Medical Monitor', 'Evaluate the initial elevation in LFT per the following assessments', 'Table 6 (all assessments to be performed once)', 'Hematology, serum chemistry, LFT, and coagulation per', 'Table 5', 'AT', 'Monitor at least weekly (hematology, serum chemistry, LFT, and', 'coagulation per Table 5 and AT) until ALT and/or AST is', 'declining on two consecutive draws, then may decrease monitoring', 'to biweekly', 'If ALT or AST rises to >5x ULN following repeat dosing,', 'permanently discontinue dosing', 'ULN', 'Permanently discontinue dosing after confirmation of the transaminase', 'value', 'Note: In addition to these criteria, other assessments or evaluations may be performed per', 'Investigator discretion, as appropriate.', 'Property of the Sanofi Group - strictly confidential', '44', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '6.2.4.', 'Preparation, Handling, and Storage', 'Qualified staff at each clinical study center will be responsible for preparation of fitusiran doses,', 'according to procedures detailed in the Pharmacy Manual. No special procedures for the safe', 'handling of IMP are required.', 'Investigational medicinal product will be stored per the Pharmacy Manual and refrigerated at', 'approximately 5=3\u00b0C. Deviations from the recommended storage conditions should be reported', 'to the Sponsor and use of the IMP halted until authorization for its continued use has been', 'provided by the Sponsor or designee, as described in the Pharmacy Manual.', 'A Sponsor representative or designee will be permitted, upon request, to audit the supplies,', 'storage, dispensing procedures, and records.', 'Instructions specific to unused IMP and additional storage details are provided in the Pharmacy', 'Manual.', '6.2.5.', 'Packaging and Labeling', 'All packaging, labeling, and production of IMP will be in compliance with current Good', 'Manufacturing Practices, or local applicable regulations, where necessary. Investigational', 'medicinal product labels and external packaging will include all appropriate information as per', 'local labeling requirements. Additional details will be available in the Pharmacy Manual.', '6.2.6.', 'Accountability', 'The Investigator or designee will maintain accurate records of receipt and the condition of the', 'IMP supplied for this study, including dates of receipt. In addition, accurate records will be kept', 'of when and how much IMP is dispensed and administered to each patient in the study. Any', 'reasons for departure from the protocol dispensing regimen must also be recorded.', 'At the completion of the study, there will be a final reconciliation of all IMP.', 'Further instructions about drug accountability are detailed in the Pharmacy Manual.', 'Any quality issue noticed with the receipt or use of an IMP (deficiency in condition, appearance,', 'pertaining documentation, labeling, expiration date, etc) must be promptly notified to the', 'Sponsor. Some deficiencies may be recorded through a complaint procedure (see Section', '7.5.6.8).', 'A potential defect in the quality of IMP may be subject to initiation of a recall procedure by the', 'Sponsor. In this case, the Investigator will be responsible for promptly addressing any request', 'made by the Sponsor, in order to recall the IMP and eliminate potential hazards.', 'Under no circumstances will the Investigator supply IMP to a third party (except for duties and', 'taxes paid [DTP] shipment, for which a courier company has been approved by the Sponsor),', 'allow the IMP to be used other than as directed by this clinical trial protocol, or dispose of IMP', 'in any other manner.', '6.3.', 'Concomitant Medications', \"Use of concomitant medications will be recorded on the patient's eCRF as specified in the\", 'Schedule of Assessments (Table 1). This includes all prescription medications, herbal', 'Property of the Sanofi Group - strictly confidential', '45', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}